ONK Therapeutics develops off‑the‑shelf, genetically engineered natural killer (NK) cell therapies that are optimized for enhanced tumor homing, persistence, and resistance to exhaustion. Their proprietary platform creates dual‑targeted NK cells with modifications such as CISH knockout, enabling simultaneous recognition of multiple cancer antigens and scalable, rapid deployment for solid and hematologic tumors. The therapies are designed for integration with other modalities, including bispecific antibodies, to improve anti‑cancer efficacy.
Funding
$21.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
1OAFounders
Product
Problem
Current cancer immunotherapies often rely on patient-specific cell products or limited targeting mechanisms, leading to manufacturing complexity, high costs, and suboptimal efficacy against solid tumors and hematological malignancies.
Solution
ONK Therapeutics develops off-the-shelf natural killer (NK) cell therapies that are genetically optimized for enhanced tumor homing, persistence, and resistance to exhaustion within the tumor microenvironment. By employing a proprietary engineering platform, the company creates dual‑targeted NK cells capable of simultaneously recognizing multiple cancer antigens, improving cytotoxic activity against both solid and hematologic cancers. The off-the-shelf format enables scalable manufacturing and rapid deployment, while the engineered modifications—such as CISH knockout—boost NK cell activation and in‑vivo durability. These therapies are designed to be combined with other modalities, such as bispecific antibodies, to further increase therapeutic synergy.
Target Audience
Primary customers are oncology clinical programs and pharmaceutical partners seeking scalable, allogeneic NK cell therapies for the treatment of solid tumors and hematological cancers.
Features
- Proprietary platform for optimal genetic engineering of NK cells, including CISH knockout to enhance activation
- Dual‑targeted receptor design enabling simultaneous recognition of two tumor antigens
- Modifications that improve tumor homing, in‑vivo persistence, and resistance to microenvironment‑induced exhaustion
- Off‑the‑shelf cell product allowing standardized manufacturing and immediate availability
- Compatibility with combination strategies, such as bispecific antibodies, to augment anti‑cancer efficacy